Femoral shaft fractures in the elderly - Role of prior bisphosphonate therapy

Injury

Volumn 42, Issue 7, 2011, Pages 702-706

  Ng, Y H ^a   Gino, P D ^a   Lingaraj, K ^a   Das De, S ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Alendronate; Bisphosphonates; Elderly; Femoral shaft fracture; Insufficiency fracture; Low impact; Prodromal pain; Radiographic features; Treatment protocol

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE[1-34];

ADULT; AGED; ARTICLE; BONE DENSITY; COMPRESSION FRACTURE; DRUG EFFICACY; DRUG SUBSTITUTION; ELDERLY CARE; FEMALE; FEMUR SHAFT FRACTURE; FRACTURE FIXATION; FRACTURE NONUNION; HOSPITAL ADMISSION; HUMAN; LEG PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OSTEOSCLEROSIS; PRIORITY JOURNAL; RADIOGRAPHY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMORAL FRACTURES; HUMANS; RETROSPECTIVE STUDIES; TERIPARATIDE;

EID: 79958043455     PISSN: 00201383     EISSN: 18790267     Source Type: Journal    
DOI: 10.1016/j.injury.2010.12.019     Document Type: Article

References (37)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41. (Pubitemid 26411651)
2. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38. (Pubitemid 46021497)
3. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99. (Pubitemid 38339363)
4. Bostman O, Varjonen L, Vainionpaa S, et al. Incidence of local complications after intramedullary nailing and after plate fixation of femoral shaft fractures. J Trauma 1989;29:639-45. (Pubitemid 19156499)
5. Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002;17:2237-46. (Pubitemid 35416758)
6. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009;91:2556-61.
7. Das De S, Setiobudi T, Shen L. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br 2010;92:679-86.
8. Dobnig H, Stepan JJ, Burr DB, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 2009;24:1998-2006.
9. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51. (Pubitemid 41094385)
10. Fleisch HA. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 1997;29:55-62. (Pubitemid 27107621)
11. Goddard MS, Reid KR, Johnston JC, Khanuja HS. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 2009:32.
12. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89:349-53. (Pubitemid 46563912)
13. Jobke B, Pfeifer M, Minne HW. Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res 2009;50:46-54.
14. Khan AA, Sandor GK, Dore E, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-90.
15. Komatsubara S, Mori S, Mashiba T, et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003;18:512-20. (Pubitemid 36241068)
16. Komatsubara S, Mori S, Mashiba T, et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004;19:999-1005. (Pubitemid 41103457)
17. Kootstra G. Femoral shaft fractures in adults. A study of 329 consecutive cases with a statistical analysis of different methods of treatment. University of Groningen; 1973.
18. Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224-31.
19. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009;20:1353-62.
20. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001;69:281-6. (Pubitemid 33140938)
21. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl 1999;101:18-26. (Pubitemid 29216601)
22. Mashiba T, Mori S, Burr DB, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005;23(Suppl. 36-42).
23. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8. (Pubitemid 41138965)
24. McKenna MJ, Kleerekoper M, Ellis BI, et al. Atypical insufficiency fractures confused with Looser zones of osteomalacia. Bone 1987;8:71-8. (Pubitemid 17108981)
25. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008;93:3785-93.
26. Mooney VCB. Fractures of the shaft of the femur. In: Rockwood Jr CA, Green DP, editors. Fractures in adults, 2nd ed., vol. 2. Philadelphia: JB Lippincott Company; 1984. p. 1357-428.
27. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-50. (Pubitemid 351630250)
28. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301. (Pubitemid 40463979)
29. Pazianas M, Blumentals WA, Miller PD. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 2008;19:773-9.
30. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59.
31. Salminen ST, Pihlajamaki HK, Avikainen VJ, Bostman OM. Population based epidemiologic and morphologic study of femoral shaft fractures. Clin Orthop Relat Res 2000:241-9. (Pubitemid 30159452)
32. Stepan JJ, Burr DB, Li J, et al. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int 2010.
33. Stock JL, Bell NH, Chesnut 3rd CH et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103:291-7. (Pubitemid 27459255)
34. Tang SY, Allen MR, Phipps R, et al. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009;20:887-94.
35. Tashjian Jr AH, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002;17:1151-61. (Pubitemid 34680490)
36. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21.
37. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7. (Pubitemid 37064708)